47. Liu XG, Morton CR, Azkue JJ, Zimmermann M, Sandkuhler J (1998) Long- term depression of C-fibre-evoked spinal field potentials by stimulation of primary afferent A delta-fibres in the adult rat. Eur J Neurosci 10: 3069–3075. 48. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229–263. 49. Huang WL, King VR, Curran OE, Dyall SC, Ward RE, et al. (2007) A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 130: 3004–3019. 50. Vahedi K, Atlan P, Joly F, Le BA, Evard D, et al. (2005) A 3-month double- blind randomised study comparing an olive oil- with a soyabean oil-based intravenous lipid emulsion in home parenteral nutrition patients. Br J Nutr 94: 909–916. 51. Bhattacharya AA, Grune T, Curry S (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 303: 721–732. 52. Vahidy WH, Ong WY, Farooqui AA, Yeo JF (2006) Effects of intracerebroven- tricular injections of free fatty acids, lysophospholipids, or platelet activating factor in a mouse model of orofacial pain. Exp Brain Res 174: 781–785. 53. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, et al. (1990) Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects. Arthritis Rheum 33: 810–820. 54. Oh YT, Lee JY, Lee J, Kim H, Yoon KS, et al. (2009) Oleic acid reduces lipopolysaccharide-induced expression of iNOS and COX-2 in BV2 murine microglial cells: possible involvement of reactive oxygen species, p38 MAPK, and IKK/NF-kappaB signaling pathways. Neurosci Lett 464: 93–97. 55. Schmitt AB, Breuer S, Liman J, Buss A, Schlangen C, et al. (2003) Identification of regeneration-associated genes after central and peripheral nerve injury in the adult rat. BMC Neurosci 4: 8. 56. DeWille JW, Farmer SJ (1992) Postnatal dietary fat influences mRNAS involved in myelination. Dev Neurosci 14: 61–68. 57. Granda B, Tabernero A, Tello V, Medina JM (2003) Oleic acid induces GAP-43 expression through a protein kinase C-mediated mechanism that is independent of NGF but synergistic with NT-3 and NT-4/5. Brain Res 988: 1–8. 58. Giehl KM, Tetzlaff W (1996) BDNF and NT-3, but not NGF, prevent axotomy- induced death of rat corticospinal neurons in vivo. Eur J Neurosci 8: 1167–1175. 59. Menei P, Montero-Menei C, Whittemore SR, Bunge RP, Bunge MB (1998) Schwann cells genetically modified to secrete human BDNF promote enhanced axonal regrowth across transected adult rat spinal cord. Eur J Neurosci 10: 607–621. 60. Cadden SW, Villanueva L, Chitour D, LeBars D (1983) Depression of activities of dorsal horn convergent neurones by propriospinal mechanisms triggered by noxious inputs; comparison with diffuse noxious inhibitory controls (DNIC). Brain Res 275: 1–11. 61. Courtine G, Song B, Roy RR, Zhong H, Herrmann JE, et al. (2008) Recovery of supraspinal control of stepping via indirect propriospinal relay connections after spinal cord injury. Nat Med 14: 69–74. 62. Ward RE, Huang W, Curran OE, Priestley JV, Michael-Titus AT (2010) Docosahexaenoic acid prevents white matter damage after spinal cord injury. J Neurotrauma 27: 1769–1780. 63. Alberts GL, Chio CL, Im WB (2001) Allosteric modulation of the human 5- HT(7A) receptor by lipidic amphipathic compounds. Mol Pharmacol 60: 1349–1355. 64. Doly S, Fischer J, Brisorgueil MJ, Verge D, Conrath M (2005) Pre- and postsynaptic localization of the 5-HT7 receptor in rat dorsal spinal cord: immunocytochemical evidence. J Comp Neurol 490: 256–269. 65. Hamon M, Kayser V, Bourgoin S (2008) Neuropathic pain: Physiopathological mechanisms and therapeutic perspectives. Bull Acad Natl Med 192: 921–926. 66. Dogrul A, Ossipov MH, Porreca F (2009) Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptors. Brain Res 1280: 52–59. 67. Nagy GG, Watanabe M, Fukaya M, Todd AJ (2004) Synaptic distribution of the NR1, NR2A and NR2B subunits of the N-methyl-d-aspartate receptor in the rat lumbar spinal cord revealed with an antigen-unmasking technique. Eur J Neurosci 20: 3301–3312. 68. Temkin R, Lowe D, Jensen P, Hatt H, Smith DO (1997) Expression of glutamate receptor subunits in alpha-motoneurons. Brain Res Mol Brain Res 52: 38–45. Albumin-Oleic Acid Treatment of Spinal Cord Injury 69. Prybylowski KL, Grossman SD, Wrathall JR, Wolfe BB (2001) Expression of splice variants of the NR1 subunit of the N-methyl-D-aspartate receptor in the normal and injured rat spinal cord. J Neurochem 76: 797–805. 70. Xu XJ, Dalsgaard CJ, Wiesenfeld-Hallin Z (1992) Spinal substance P and N- methyl-D-aspartate receptors are coactivated in the induction of central sensitization of the nociceptive flexor reflex. Neuroscience 51: 641–648. 71. Brenner GJ, Ji RR, Shaffer S, Woolf CJ (2004) Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC- dependent site, serine-896, in spinal cord dorsal horn neurons. Eur J Neurosci 20: 375–384. 72. Roh DH, Seo HS, Yoon SY, Song S, Han HJ, et al. (2010) Activation of spinal alpha-2 adrenoceptors, but not mu-opioid receptors, reduces the intrathecal N- methyl-D-aspartate-induced increase in spinal NR1 subunit phosphorylation and nociceptive behaviors in the rat. Anesth Analg 110: 622–629. 73. Fleming JC, Norenberg MD, Ramsay DA, Dekaban GA, Marcillo AE, et al. (2006) The cellular inflammatory response in human spinal cords after injury. Brain 129: 3249–3269. 74. Jones TB, McDaniel EE, Popovich PG (2005) Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 11: 1223–1236. 75. Holmoy T, Skorstad G, Roste LS, Scheie D, Alvik K (2009) Stiff person syndrome associated with lower motor neuron disease and infiltration of cytotoxic T cells in the spinal cord. Clin Neurol Neurosurg 111: 708–712. 76. Feng X, Zhang F, Dong R, Li W, Liu J, et al. (2009) Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Eur J Pharmacol 614: 38–43. 77. Yezierski RP (2009) Spinal cord injury pain: spinal and supraspinal mechanisms. J Rehabil Res Dev 46: 95–107. 78. Widerstrom-Noga EG, Finnerup NB, Siddall PJ (2009) Biopsychosocial perspective on a mechanisms-based approach to assessment and treatment of pain following spinal cord injury. J Rehabil Res Dev 46: 1–12. 79. Biering-Sorensen F, Nielsen JB, Klinge K (2006) Spasticity-assessment: a review. Spinal Cord 44: 708–722. 80. Nielsen JB, Crone C, Hultborn H (2007) The spinal pathophysiology of spasticity-from a basic science point of view. Acta Physiol (Oxf) 189: 171–180. 81. Cruz-Almeida Y, Felix ER, Martinez-Arizala A, Widerstrom-Noga EG (2009) Pain symptom profiles in persons with spinal cord injury. Pain Med 10: 1246–1259. 82. Gomez-Soriano J, Castellote JM, Perez-Rizo E, Esclarin A, Taylor JS (2010) Voluntary ankle flexor activity and adaptive coactivation gain is decreased by spasticity during subacute spinal cord injury. Exp Neurol 224: 507–516. 83. Adams MM, Hicks AL (2005) Spasticity after spinal cord injury. Spinal Cord 43: 577–586. 84. Taricco M, Pagliacci MC, Telaro E, Adone R (2006) Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review. Eura Medicophys 42: 5–15. 85. Baastrup C, Finnerup NB (2008) Pharmacological management of neuropathic pain following spinal cord injury CNS Drugs. 22: 455–475. 86. Tullis JL (1977) Albumin. 2. Guidelines for clinical use. JAMA 237: 460–463. 87. Wang YF, Gwathmey JK, Zhang G, Soriano SG, He S, et al. (2005) Cerebrospinal fluid may mediate CNS ischemic injury. Cerebrospinal Fluid Res 2: 7. 88. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132: 171–183. 89. Bhattacharya AA, Grune T, Curry S (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 303: 721–732. 90. Chuang VT, Kragh-Hansen U, Otagiri M (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19: 569–577. 91. Banks WA, Broadwell RD (1994) Blood to brain and brain to blood passage of native horseradish peroxidase, wheat germ agglutinin, and albumin: pharma- cokinetic and morphological assessments. J Neurochem 62: 2404–2419. 92. Belayev L, Marcheselli VL, Khoutorova L, Rodriguez de Turco EB, Busto R, et al. (2005) Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 36: 118–123. 93. Bento-Abreu A, Tabernero A, Medina JM (2007) Peroxisome proliferator- activated receptor-alpha is required for the neurotrophic effect of oleic acid in neurons. J Neurochem 103: 871–881. PLoS ONE | www.plosone.org 14 October 2011 | Volume 6 | Issue 10 | e26107